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The HIV-1 accessory protein Vpu counteracts a host
factor that restricts virion release from infected cells.
Here we show that the interferon-induced cellular
protein BST-2/HM1.24/CD317 is such a factor.
BST-2 is downregulated from the cell surface by
Vpu, and BST-2 is specifically expressed in cells
that support the vpu phenotype. Exogenous expres-
sion of BST-2 inhibits HIV-1 virion release, while
suppression of BST-2 relieves the requirement for
Vpu. Downregulation of BST-2 requires both the
transmembrane/ion channel domain and conserved
serines in the cytoplasmic domain of Vpu. Endoge-
nous BST-2 colocalizes with the HIV-1 structural
protein Gag in endosomes and at the plasma mem-
brane, suggesting that BST-2 traps virions within
and on infected cells. The unusual structure of
BST-2, which includes a transmembrane domain
and a lumenal GPI anchor, may allow it to retain
nascent enveloped virions on cellular membranes,
providing a mechanism of viral restriction counter-
acted by a specific viral accessory protein.
INTRODUCTION
Viral ‘‘accessory’’ proteins are so named due to their relative
dispensability for replication in simple in vitro culture systems,
an observation often explained by their roles in evasion of innate
and adaptive immunity in the infected host (Sheehy et al., 2002;
Collins et al., 1998). Specific in vitro culture systems may not
reveal the phenotype of such genes, if the cells used do not
express the inhibitory cellular factors that these genes counter-
act (Sheehy et al., 2002). The HIV-1 accessory gene vpu encodes
a small transmembrane protein known to enhance the release of
infectious progeny virions from infected cells, but only in certain
cell types (Klimkait et al., 1990; Sakai et al., 1995). Heterokaryons
formed by the fusion of cells that support the phenotype of vpu
with cells that do not are supportive of the Vpu effect, suggesting
that Vpu counteracts an inhibitor of virion release (Varthakavi
et al., 2003). Cells that do not support the effect of Vpu can beinduced to do so by treatment with type I interferons, suggesting
that the inhibitor is a component of the interferon-mediated
innate immune response to viral infection (Neil et al., 2007).
The inefficient release of virions in the absence of Vpu is
associated with the accumulation of nascent virions along the
plasma membrane and within clathrin-coated endosomes
(Klimkait et al., 1990; Van Damme and Guatelli, 2007). Virions
trapped on the plasma membrane can be released by treatment
with proteases, suggesting that the inhibitor that Vpu overcomes
is a cell surface-associated protein (Neil et al., 2006). We were
intrigued by the proteomic analysis of Bartee and colleagues,
who revealed downregulation of the interferon-inducible protein
BST-2/CD317/HM1.24 from the plasma membrane by the Kapo-
si’s sarcoma associated herpes virus (KSHV) protein K5, an
immunomodulatory viral ubiquitin ligase; BST-2 was also noted
to be modulated by HIV-1 Vpu (Bartee et al., 2006). Based on
these data, we hypothesized that BST-2 is the inhibitor of virion
release that is counteracted by Vpu. This hypothesis has been
supported by the recent findings of Neil and colleagues, who
refer to BST-2/CD317 as ‘‘tetherin’’ based on its ability to inhibit
the release of HIV virions from cells (Neil et al., 2008). The data
herein corroborate the role of BST-2/CD317 as the elusive
restriction factor targeted by Vpu and further suggest that
downregulation of BST-2 from the cell surface is the mechanism
by which Vpu counteracts this cellular antiviral defense.
RESULTS
HIV-1 Vpu Downregulates BST-2 from the Cell Surface
Using flow cytometry, we determined that BST-2 is constitutively
expressed on the surface ofHeLacells and that it isdownregulated
by Vpu as expressed via transient transfection (Figure 1A). The ex-
tent of downregulation of BST-2 in highly expressing cells was ap-
proximately 10-fold. Downregulation of BST-2 was also observed
using Vpu-GFP fusion proteins in which the Vpu sequence was ob-
tained from a laboratory-adapted subtype B virus (HXB2) as well
as from a clinical isolate of subtype C from Botswana (Figure 1B).
Expression of BST-2 at the Cell Surface Correlates
with the Requirement of Vpu for Efficient Virion Release
BST-2 was expressed robustly on CEM T cells, a CD4-positive
leukemic cell line, as well as on HeLa cells, but was nearlyCell Host & Microbe 3, 245–252, April 2008 ª2008 Elsevier Inc. 245
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Vpu Counteracts BST-2, an Inhibitor of HIV ReleaseFigure 1. BST-2/CD317 Is Downregulated from the Cell Surface by
HIV-1 Vpu, It Is Expressed Constitutively in a Cell Type-Specific
Manner that Correlates with the Virology of Vpu, and Its Expression
Is Induced by Interferon-a
(A) HeLa cells were transfected to express transiently either no viral protein
(‘‘control vector’’) or a codon-optimized version of HIV-1NL4-3 Vpu (‘‘pVphu’’)
along with GFP encoded on a separate plasmid, then stained the next day
for surface BST-2/CD317 and analyzed by two-color flow cytometry.
(B) HeLa cells were transfected to express transiently GFP fusion proteins con-
taining N-terminal Vpu of clade BHXB-2 or clade C, then stained the next day for
surface BST-2/CD317 and analyzed by two-color flow cytometry. Numbers
within each panel are the mean fluorescence intensities of cell surface BST-
2 for the low- to mid-GFP-positive cells (green). Note that the GFP moiety
appeared to interfere with the activity of Vpu at high levels of expression.
(C) Cell surface expression of BST-2 in HeLa cells (clone P4.R5), HEK293 cells,
and CEM T lymphoblastoid cells measured using flow cytometry.
(D) Virologic effects of Vpu in the different host cells. (Left two panels) Percent
p24 capsid secretion measured as the fraction of the total p24 capsid antigen
produced by cultures of cells transfected with full-length viral genomes that
was secreted into the media. (Right panel) Growth curve of wild-type (‘‘WT’’)
versus vpu-negative (‘‘DVpu’’) virus during spreading infection in CEM T cells.
‘‘1’’ and ‘‘2’’ indicate independently infected cultures. Error bars are the stan-
dard deviation. The difference between the concentrations of p24 antigen in
the media of cultures infected with wild-type or DVpu at 9 days after inocula-
tion was significant (p = 0.001 by Student’s t test).
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pattern of expression matched the ability of these cells to support
the effect of Vpu on virion release (Figure 1D). Treatment of
HEK293 cells with interferon-a induced the expression of BST-2
(Figure 1E), consistent with the ability of type I interferons to confer
Vpu-dependent virion release to these cells (Neil et al., 2007).
BST-2 Inhibits the Release of Virions from Cells
To determine whether BST-2 is an inhibitor of virion release, we
expressed the protein in HEK293 cells by transient transfection
together with full-length HIV-1 proviral DNA (Figure 2). BST-2
was a strikingly potent inhibitor of virion release. Relatively
selective inhibition of virus lacking a vpu gene occurred only
when very low amounts of plasmid expressing BST-2 were
used: when the weight ratio of cotransfected plasmids express-
ing BST-2 and the HIV genome was 1:400, Vpu enhanced the ef-
ficiency of virion release by approximately two-fold (Figure 2B).
This effect of Vpu was reproducible and not increased by further
reduction in BST-2 expression (data not shown). In contrast, at
higher concentrations, the release of both wild-type as well as
vpu-negative virus was markedly inhibited, suggesting that the
ability of Vpu to counteract the inhibitory action of BST-2 is
readily saturated.
BST-2 Is Necessary for the Maximal Effect of Vpu
on Virion Release
To determine whether BST-2 is necessary for the effect of Vpu,
we inhibited the expression of the protein in HeLa cells by RNA
interference (Figure 3). Plasmid vectors encoding short hairpin
RNAs (shRNAs) effectively inhibited the expression of BST-2 at
the surface of HeLa cells (Figure 3A). Expression of these shRNAs
reduced the phenotype of the vpu gene: the release of virions
from cells expressing vpu-negative virus was increased much
more than the release of virions from cells expressing the wild-
type (Figure 3B). Expression of an ‘‘off-target’’ shRNA had no
effect (data not shown). The incomplete rescue of virion release
from cells expressing vpu-negative virus likely reflects the high
potency of BST-2 as shown above, although alternatively, it could
indicate that BST-2 is not the sole protein mediating inhibition of
virion release in these cells. Interestingly, the small but consistent
increase in the release of virions from cells expressing wild-type
virus by these shRNAs suggests that the activity of BST-2 is not
fully negated by Vpu during viral replication.
Vpu Downregulates BST-2 When Expressed
in the Context of the Complete Viral Genome:
Role of the Vpu Transmembrane Domain
and Conserved Serines in the Cytoplasmic Domain
To determine the requirements in Vpu for the downregulation of
BST-2 and to characterize this effect in the context of the com-
plete viral genome, we expressed proviral mutants of HIV-1 in
(E) Induction of BST-2 expression at the surface of HEK293 cells by treatment
with IFN-a. Cells were treated overnight with the indicated concentrations of
interferon, then analyzed by flow cytometry.
In (A)–(C), horizontal and vertical lines indicate gates set using either GFP-neg-
ative cells or a primary antibody isotype control for BST-2; colors are arbitrary
and distinguish GFP-negative, -low-positive, and -high-positive cells. In (E),
the leftmost vertical line is the gate set using an antibody isotype control.
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downregulated BST-2 from the cell surface. This effect required
the vpu gene. To examine the roles of Vpu domains, we tested
the proviral mutant VpuRD, which encodes a Vpu transmem-
brane domain (TMD) of scrambled sequence, and the mutant
Vpu2/6, which encodes alanine substitutions of serine residues
52 and 56 in the Vpu cytoplasmic domain. Both the VpuRD
and Vpu2/6 mutants were impaired in their abilities to downregu-
late BST-2. These domains of Vpu have been associated with
distinct functional attributes: the TMD with ion channel activity
and serines 52 and 56 with the linkage of Vpu to b-TrCp and
a Skp1-ubiquitin ligase, through which it triggers the degradation
of CD4, the primary viral receptor (Schubert et al., 1996a., 1996b;
Margottin et al., 1998). However, both domains contribute to the
enhancement of virion release by Vpu (Figure 4B; Schubert et al.,
1996b; Schubert and Strebel, 1994). To test the hypothesis that
Vpu downregulates BST-2 via the proteasome, we examined
whether the peptide aldehyde proteasome inhibitor MG-132
blocked this activity (Figure 4C). Only a modest effect of
MG-132 was observed, consistent with an alternative mecha-
nism that is independent of proteasomal activity.
Vpu and Endogenous BST-2 Colocalize within
the Cytoplasm of Cells Expressing the Viral Genome
To determine whether Vpu might affect BST-2 within the endoso-
mal system, we examined the subcellular distributions of these
proteins in HeLa cells expressing Vpu from the complete HIV-1
genome. Native, endogenous BST-2 colocalized with Vpu within
cytoplasmic structures visualized by immunofluorescence
microscopy (Figure 5). The nonfunctional Vpu expressed by
the VpuRD mutant colocalized slightly less extensively with
BST-2. These data suggest that coresidence of Vpu and BST-
2 within the endosomal system may be functionally important.
Figure 2. Exogenous Expression of BST-2 in HEK293
Cells Inhibits Virion Release
(A) HEK293 cells were transfected to express either no protein
(‘‘empty vector’’) or BST-2 (‘‘BST-2’’) and analyzed by flow
cytometry for surface BST-2; 1.6 mg of DNA was used in
each transfection. The leftmost vertical line is the gate set
using an antibody isotype control.
(B) HEK293 cells were transfected to express transiently the
wild-type and vpu-negative HIV-1 genomes together with
either no BST-2 (‘‘empty vector’’) or BST-2. Ratios are the
relative amounts of plasmids by weight (empty vector or
BST-2 vector:proviral [HIV-1] vector); total DNA was 1.6
mg in each transfection. The following day, the fraction of
the total p24 capsid antigen produced that was secreted
into the media was measured. Error bars are the standard
deviation.
Figure 3. Reduction of Constitutive BST-2 Expression
in HeLa Cells Decreases the Virologic Phenotype of
vpu
(A) HeLa cells were transfected to express transiently either no
short hairpin (sh) RNA (‘‘empty vector’’) or various shRNAs
targeting different sequences in BST-2 mRNA (‘‘TI-1,’’ ‘‘TI-
3,’’ or ‘‘TI-4’’), along with GFP encoded on a separate plasmid,
then stained 3 days later for surface BST-2/CD317 and
analyzed by two-color flow cytometry. Horizontal and vertical
lines indicate gates set using either GFP-negative cells or a pri-
mary antibody isotype control for BST-2; colors are arbitrary
and distinguish GFP-negative, -low-positive, and -high-posi-
tive cells. Total DNA in each transfection was 1.6 mg, 1.4 of
which was the shRNA expression vector.
(B) HeLa cells were transfected to express either no shRNA or
shRNAs TI-1, -3, -4, or an equimolar mixture of TI-1, -3, and -4,
along with wild-type or vpu-negative full-length viral DNA at
a weight ratio of 2:1::shRNA-vector:proviral plasmid. A
CXCR4 receptor blocker (AMD3100) was used to limit viral
production to the initially transfected cells, and the fraction
of the total p24 capsid antigen produced that was secreted
into the media was measured 2 days later. Error bars are the
standard deviation.
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Both in Endosomes and along the Plasma Membrane
The accumulation of virions along the plasma membrane and
within endosomes of cells expressing vpu-negative virus led to
the hypothesis that a specific cellular factor ‘‘tethers’’ nascent
virions to cellular membranes (Neil et al., 2006). If BST-2 is this
factor, then it should colocalize microscopically with virion struc-
tural proteins along the plasma membrane and in endosomes.
To test this, we first expressed complete viral genomes in
HeLa cells and costained the cells for both p55/p17 Gag and
endogenous, native BST-2 (Figure 6A). As described previously,
the accumulation of Gag in endosomal structures and along the
plasma membrane was more prominent in the absence of vpu
(Klimkait et al., 1990; Neil et al., 2006; Van Damme and Guatelli,
2007). Nevertheless, in cells expressing either wild-type or
vpu-negative virus, BST-2 and HIV-1 Gag colocalized both along
the plasma membrane and in endosomes, consistent with the
hypothesis that BST-2 traps virions on and within virus-produc-
ing cells. Similar results were obtained using HEK293 cells
expressing exogenous BST-2 (Figure 6B).
BST-2 Traps Viral Particles on the Cell Surface
To determine whether BST-2 is able to retain nascent virions at
the cell surface, we used scanning electron microscopy (SEM)
to visualize virus-like particles (VLPs) on the surface of HEK293
and HT1080 cells; neither of these cell types supports the effect
of Vpu on virion release, and neither expresses BST-2 (Figure 1;
Neil et al., 2008). The VLPs were expressed from a proviral
genome lacking vpu as well as vpr, vif, env, and nef genes. The
density of VLPs on the surface of HEK293 or HT1080 cells was
typically low (Figures 7A and 7B and 7E and 7F), but when the
cells were transfected to express BST-2, we observed surface
Figure 4. Vpu-Mediated Downregulation of BST-2 in
the Context of the Complete HIV-1 Genome Requires
the Vpu Transmembrane Domain and Conserved Ser-
ines in the Cytoplasmic Domain but Is Not Prevented
by Inhibition of the Proteasome
(A) HeLa cells were transfected to express complete HIV-1
genomes, either wild-type (‘‘WT’’), vpu-negative (‘‘DVpu’’),
a mutant encoding a Vpu protein whose transmembrane
domain is scrambled (‘‘VpuRD’’), or a mutant in which serines
52 and 56 in the Vpu cytoplasmic domain are replaced by
alanines (‘‘Vpu2/6’’), in each case along with GFP encoded
on a separate plasmid. The cells were stained the next day
for surface BST-2 and analyzed by two-color flow cytometry.
(B) HeLa cells were transfected with the indicated proviral
genomes, and the fraction of the total p24 capsid antigen
produced that was secreted into the media was measured 1
day later. Error bars are the standard deviation.
(C) HeLa cells were transfected to express transiently either
no viral protein (‘‘mock’’) or a codon-optimized version of
HIV-1NL4-3 Vpu along with GFP encoded on a separate plas-
mid. The next day, cells were either treated for 5 hr with 25 mM
MG-132 (an inhibitor of the proteasome) or left untreated,
then stained for surface BST-2 and analyzed by two-color
flow cytometry.
In (A) and (C), horizontal and vertical lines indicate gates set
using either GFP-negative cells or a primary antibody isotype
control for BST-2; colors are arbitrary and distinguish GFP-
negative, -low-positive, and -high-positive cells.
Figure 5. BST-2 Colocalizes with Vpu
HeLa cells were transfected to express transiently
either the wild-type or VpuRD viral genomes. The
next day, the cells were stained by indirect immu-
nofluorescence using antibodies to BST-2 and
Vpu. Images were obtained using a spinning disc
confocal microscope and processed using a
deconvolution algorithm; single planes are shown.
Insets show the boxed regions indicated in the
‘‘merge’’ panels. Vpu, green; BST-2, red. Scale
bars are 10 mm.
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7D and 7G and 7H). These data suggest that BST-2 acts at least
in part by trapping virions at the cell surface.
DISCUSSION
We have shown that the HIV-1 Vpu protein downregulates the
interferon-induced cellular protein BST-2/HM1.24/CD317 from
cell surfaces. BST-2 is a potent inhibitor of HIV-1 virion release,
and it appears both sufficient to confer vpu-dependent virion
release to HEK293 cells and necessary for a robust vpu pheno-
type in HeLa cells.
BST-2 has an unusual topology that may render it uniquely
suited to tethering nascent enveloped virions to cellular mem-
branes: it is a type II transmembrane protein whose lumenal
domain is predicted to be modified by linkage to glycosylphos-
phatidylinositol (GPI) (Kupzig et al., 2003). This structure could
enable BST-2 to function as a bifunctional lipid-binding agent
that directly links cellular and viral membranes. BST-2 associ-
ates with cholesterol-enriched lipid rafts, presumably via its
GPI anchor, and it has been proposed to crosslink rafts by di-
merization (Kupzig et al., 2003). HIV-1, as well as several other
enveloped viruses including influenza A and Ebola virus, has
cholesterol-enriched lipid membranes due to budding from
raft-enriched domains (Aloia et al., 1993; Scheiffele et al.,
1999; Nguyen and Hildreth, 2000; Panchal et al., 2003). Conse-
quently, it is tempting to speculate that BST-2 may inhibit the
release of a number of enveloped viruses, especially those
that bud from cholesterol-enriched rafts. This hypothesis is
consistent with the ability of Vpu to enhance the release of mu-
rine leukemia virus and Ebola virus-like particles (Neil et al.,
2007; Gottlinger et al., 1993), as well as with the observation
that downregulation of BST-2 is a function of proteins encoded
by proteins of both HIV-1 (Vpu) and KSHV (K5), viruses that
have little in common except a lipid envelope (Bartee et al.,
2006).
Although BST-2 is a ubiquitous protein following interferon
stimulation, it is expressed constitutively on B cells, dendritic
cells, and activated T cells (Vidal-Laliena et al., 2005; Blasius
et al., 2006). Until now, its function has been essentially
unknown. Activated T cells are a major host cell for productive
HIV-1 replication in vivo, where the inhibitory effect of BST-2
on virion release could play a role in restricting viral replication,
consistent with the significant effect of Vpu on replication and
pathogenesis in animal models (Hout et al., 2005). In addition,
BST-2 could play a role in capturing enveloped viruses via their
lipid domains for uptake into the professional antigen presenting
cells noted above.
How does Vpu counteract the inhibitory effect of BST-2? Vpu
could decrease the expression of BST-2 by targeting it for deg-
radation, similar to the mechanism of its effect on CD4 (Schubert
et al., 1998). This hypothesis is consistent with the role of serines
52 and 56 in the cytoplasmic domain of Vpu in the downregula-
tion of BST-2 observed here (Margottin et al., 1998). However,
data herein suggest that inhibition of the proteasome does not
efficiently reverse the Vpu-mediated downregulation of BST-2
from the cell surface, a result consistent with the observation
that the effect of Vpu on virion release persists in the presence
of such inhibitors (Schubert et al., 2000). Notably, the transmem-
brane domain of Vpu and its ion channel activity have been cor-
related more closely with the virion release phenotype than have
the above serine residues (Schubert et al., 1996a). Nevertheless,
Figure 6. BST-2 Colocalizes with HIV-1 p17/
p55 Gag Both along the Plasma Membrane
and in Endosomes
(A) HeLa cells were transfected to express tran-
siently either the wild-type or vpu-negative viral
genome, along with GFP encoded on a separate
plasmid. The next day, the cells were stained by
indirect immunofluorescence using antibodies to
BST-2 and HIV-1 Gag (p17/p55). Images were ob-
tained using a spinning disc confocal microscope
and processed using a deconvolution algorithm;
single planes are shown. Insets show the boxed
regions indicated in the ‘‘merge’’ panels. GFP,
green; BST-2, red; p17/p55 Gag, blue.
(B) HEK293 cells were transfected to express tran-
siently either the wild-type or vpu-negative viral
genome along with BST-2 encoded on a separate
plasmid; the ratio of BST-2 expression plasmid:
proviral plasmid was 1:4 by weight. The next
day, the cells were stained by indirect immunoflu-
orescence using antibodies to BST-2 and HIV-1
Gag (p17/p55); images were obtained as de-
scribed above. p17/p55 Gag, green; BST-2, red.
Scale bars in all panels are 10 mm.
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the transmembrane domain contribute to optimal virion release
(Schubert et al., 1996b; Schubert and Strebel, 1994).
Conceivably, the ion channel activity of Vpu could affect the
intracellular trafficking of BST-2, which, although readily detect-
able by flow cytometry at the surface of cells such as HeLa,
CEM, and interferon-treated HEK293, is observed to a large
extent within the endosomal system by immunofluorescence
microscopy. Vpu is itself found predominantly within the Golgi,
the trans-Golgi network (TGN), and the endosomal system,
and its ability to distort the TGN and delay transport through
secretory membranes could relate directly to an effect on
BST-2 (Van Damme and Guatelli, 2007; Varthakavi et al.,
2006; Vincent and Abdul Jabbar, 1995). Indeed, an ortholog of
BST-2 reportedly plays a key role in the maintenance of Golgi
structure (Li et al., 2007). Interestingly, the requirement of func-
tional recycling endosomes for the enhancement of virion
release suggests that Vpu may act on BST-2 within the endoso-
mal system (Varthakavi et al., 2006). These hypotheses are
supported by the apparent colocalization of BST-2 and Vpu
within endosomal structures.
Although we detected remarkable modulation of cell surface
BST-2 by Vpu, whether the surface level of BST-2 is a direct,
quantitative correlate of the efficiency of virion release remains
an open question. For example, the inhibition of virion release
induced by exogenous expression of BST-2 in HEK293 cells
appears to occur at surface levels below that detected on
HeLa cells. This observation, together with the ease with which
virion release is inhibited by the exogenous expression of BST-
2 in HEK293 cells even when Vpu is present, suggests that differ-
entially expressed but as yet unidentified cellular factors may
modulate the ability of BST-2 to restrict virion release and/or
the effectiveness of Vpu as a viral countermeasure.
While this paper was in preparation, similar conclusions
regarding the role of BST-2 as a restriction factor counteracted
by Vpu were reported by Neil and colleagues, although these
investigators did not address the potential effect of Vpu on the
expression of BST-2 at the cell surface as highlighted herein
(Neil et al., 2008). Nevertheless, comparison of these two data
sets reveals interesting differences in the apparent efficacy of
Vpu as an antagonist of BST-2. In the experiments herein, the
exogenous expression of BST-2 in HEK293 cells consistently
inhibited the release of wild-type virions, whereas Neil and
colleagues reported little to no effect of BST-2 expression on
the wild-type. Similarly, in the experiments herein, Vpu did not
appear to counteract fully the effect of BST-2 in HeLa cells,
because the suppression of BST-2 expression in these cells
increased the efficiency of virion release even in the case of
wild-type virus. In contrast, Neil and colleagues reported no
increase in the release of wild-type virions when the expression
of BST-2 was suppressed in HeLa cells. The reasons for these
differences are not clear, but they could be due to the different
methods used to quantify ‘‘virion release.’’ Here, we measured
the fractional secretion of p24 capsid antigen, the structural
component of the virion core; this measurement may be compli-
cated by the presence of secreted p24 antigen that is not virion
associated. Neil and colleagues measured secreted infectivity in
a virologic assay; this measurement may be complicated by
intrinsic differences in the particle/infectivity ratio of wild-type
and vpu-negative virions. While these issues remain to be fully
resolved, the magnitude of the effects of Vpu on virion release
reported here is consistent with previously reported measure-
ments (Schubert et al., 1996b; Schubert and Strebel, 1994).
As noted above, the data herein, together with those of Neil and
colleagues, raise the intriguing possibility that BST-2 is a broadly
acting inhibitor of virion release (Neil et al., 2008). Vpu has been
categorized as a virally encoded ion channel or ‘‘viroporin,’’ along
with several viral gene products including the M2 protein of influ-
enza A virus, the 6K protein of Sindbis virus, and the p7 protein of
hepatitis C virus (Gonzalez and Carrasco, 2003). Like Vpu, these
proteins affect virion release and/or protein transport along secre-
tory membranes. Given the potential for BST-2 to act as a broad
inhibitor of enveloped viruses and the role of the Vpu transmem-
brane domain in the modulation of BST-2, we wonder whether
other viroporins may downregulate BST-2 as a countermeasure
to the innate immune response of the host to viral infection.
Figure 7. BST-2 Retains VLPs at the Cell Surface
HEK293 cells (A–D) or HT1080 cells (E–H) were transfected to express
transiently a provirus lacking intact vpu, vpr, vif, env, and nef genes, along
with either a vector expressing no BST-2 (A and B; E and F) or BST-2 (C and
D; G and H). The proviral plasmid also encoded the fluorescent protein TdTo-
mato, enabling assessment of the efficiency with which individual cells were
transfected by fluorescence microscopy (insets), before visualization by
SEM. Scales bars are 2 mm.
250 Cell Host & Microbe 3, 245–252, April 2008 ª2008 Elsevier Inc.
Cell Host & Microbe
Vpu Counteracts BST-2, an Inhibitor of HIV ReleaseEXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Reagents
The proviral plasmid pNL4-3 was obtained from the National Institutes of
Health (NIH) AIDS Research & Reference Reagent Program (Adachi et al.,
1986). The pNL4-3 mutants DVpu (containing an out-of-frame deletion in the
50 region of the vpu gene that preserves the start codon and does not affect
env), VpuRD (encoding a Vpu protein in which the sequence of the transmem-
brane domain is randomized), and Vpu2/6 (encoding a Vpu protein in which
serines 52 and 56 in the cytoplasmic domain are substituted with alanines),
as well as the pcDNA3.1-based plasmid expressing codon-optimized Vpu
were provided by Klaus Strebel (Schubert et al., 1996a; Nguyen et al., 2004).
The plasmid expressing GFP, pCG-GFP, was provided by Jacek Skowronski
(Greenberg et al., 1997). Plasmids expressing the fusion proteins of GFP with
Vpu from clade B or C HIV-1 were described previously (Pacyniak et al., 2005).
The plasmid expressing BST-2 was obtained from OriGene (Rockville, MD);
the coding sequence of BST-2 was confirmed. The corresponding empty
vector, pCMV6-XL5, was also obtained from OriGene. Plasmids expressing
29-mer shRNAs targeting three distinct regions of the BST-2 mRNA (pRS:
TI357701, -3, and -4; ‘‘TI-1, TI-3, and TI-4’’), the empty vector pRS, and an
off-target control vector encoding an inactive shRNA targeted to GFP were
obtained from OriGene. The pNL4-3-derived ‘‘HIV-tomato’’ plasmid does not
express Vpr, Vif, Vpu, or Env; it encodes GFP in the nef position and the protein
TdTomato downstream of a CMV promoter located outside the proviral
sequence. The murine monoclonal antibody to BST-2/HM1.24/CD317 was
provided by Chugai Pharmaceutical Co. (Kanagawa, Japan). For flow cytom-
etry, an IgG2a antibody isotype control and a goat, anti-mouse IgG antibody
conjugated to allophycocyanin (APC) was obtained from BioLegend (San
Diego, CA). Rabbit antisera to HIV-1 Vpu and p17/p55 were obtained from
the NIH AIDS Research & Reference Reagent Program. Secondary antibodies
for immunofluorescence were obtained from Jackson ImmunoResearch (West
Grove, PA). The peptide-aldehyde proteasome inhibitor MG-132 was obtained
from Calbiochem, and the CXCR4 coreceptor antagonist AMD3100 was
obtained from Sigma-Aldrich.
Cells and Transfections
HEK293T cells were obtained from Ned Landau and were maintained in EMEM
plus 10% fetal bovine serum (FBS) and L-glutamine. HeLa P4.R5 cells were
also obtained from Ned Landau and were maintained in DMEM plus 10%
FBS, penicillin/streptomycin, and puromycin; these cells stably express CD4
and CCR5 and are a derivative of clone P4 (Clavel and Charneau, 1994).
CEM cells were obtained from Douglas Richman and maintained in RPMI
1640 plus 10% FBS and penicillin/streptomycin. HT1080 cells were obtained
from David Pintel. Cells were transfected using Lipofectamine 2000 (In-
vitrogen, Carlsbad, CA) according to the manufacturer’s instructions, or with
Fugene for electron microscopy.
Infections
For viral infections, CEM T cells were exposed for 5 hr to cell-free virions
produced from HeLa P4.R5 cells transiently transfected with proviral plasmids.
The cells were washed and the cultures were split at days 3, 6, and 9 to
maintain a nominal cell density between 4 3 105 and 2 3 106 cells/ml. The
concentrations of p24 antigen in the cell-free supernatants of the cultures
were measured by ELISA (Perkin-Elmer).
Flow Cytometry
Cells were stained before fixation in phosphate-buffered saline (PBS) including
sodium azide and FBS at 4C using an indirect method to detect BST-2: the
HM1.24 murine monoclonal antibody was followed by a goat anti-mouse
IgG conjugated to APC. Gates for BST-2 were set using an antibody isotype
control (IgG2a) as the primary antibody, and gates for GFP were set using
non-GFP-expressing cells. After staining, the cells were fixed in formaldehyde
and analyzed by flow cytometry.
Virion Release Assays
A p24 antigen capture ELISA (Perkin-Elmer) was used to determine the
concentration of viral capsid protein in culture supernatants that were first
clarified by centrifugation at 400 3 g as well as the concentration of capsidprotein in detergent lysates (0.5% Triton X-100 in PBS) of the adherent cells.
The percentage of p24 capsid secreted into the culture media was determined
as the concentration of p24 antigen in the supernatants divided by the concen-
tration of p24 antigen in the total culture (supernatant plus cells)3 100. Assays
were run in duplicate.
Immunofluorescence Microscopy
Cells were stained for HIV-1 Gag and BST-2 using the antibodies above after
fixation in 3% formaldehyde and permeabilization using 0.1% NP40, as previ-
ously described (Van Damme and Guatelli, 2007). Images were obtained using
a spinning disc confocal fluorescence microscope fitted with a 1003 objective
(Olympus). For each field, a Z-series of images was collected, and the data
were processed using a deconvolution algorithm (Slidebook software, Imaging
Innovations, Inc). Composite multicolor images of single optical sections were
assembled using Adobe Photoshop software.
SEM
SEM analyses were performed as described previously (Larson et al., 2005).
HEK293T cells or HT1080 cells were plated onto glass coverslips containing
a gold finder grid for cell identification, then transfected using Fugene (Roche)
with ‘‘HIV-tomato’’:BST-2 or ‘‘HIV-tomato’’:empty vector (pCMV6-XL5) at
a plasmid weight ratio of 50:1. Nineteen hours after transfection, cells were
fixed in 4% paraformaldehyde and imaged by fluorescence microscopy to
identify the transfected cells and assess relative transfection levels. The cells
were then fixed in 2.5% glutaraldehyde, dehydrated, critical point dried,
coated with a thin layer of platinum, and imaged at the University of Missouri
Electron Microscopy core facility on a Hitachi S4700 Cold-cathode SEM.
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